Sherika Hanley

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Vivek Shinde, Sutika Bhikha, Zaheer Hoosain et al. · New England Journal of Medicine · 2021 · 652 citations · Full text

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

Shahin Lockman, Sean S. Brummel, Lauren Ziemba et al. · The Lancet · 2021 · 152 citations · Full text

Treatment And Prevention, Antiviral Drug Development, Antiviral Therapy +9

Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

Shabir A. Madhi, Dhayendre Moodley, Sherika Hanley et al. · The Lancet HIV · 2022 · 65 citations · Full text

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages

Jinal N. Bhiman, Simone I. Richardson, Bronwen E. Lambson et al. · Scientific Reports · 2023 · 46 citations · Full text

Genetics, Immunology, Immunodominance +16

Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant

Vivek Shinde, Sutika Bhikha, Zaheer Hoosain et al. · 2021 · 42 citations · Full text

Immunology, Preliminary Efficacy, Covid-19 Epidemiology +16